Posted on

cbd hemp oil and als

However, aside from a clinical report on spasticity [10], there are unfortunately no clinical trials involving the use of CBD for ALS to confirm these effects conclusively. Therefore, all we have to go off at the moment are case studies, animal studies, in vitro research, and correlation studies.

Here, we’ll explore the potential use of CBD in ALS and offer some insight into how you can get the most out of your CBD supplementation.

Summary: Using CBD for ALS

An animal study published in 2004 investigated the role of THC — the primary psychoactive cannabinoid in the cannabis plant — on mice with ALS to measure any changes [6]. The results of this study reported that the mice who were given THC had significantly less severity with their symptoms than mice not given the THC treatments.

Eventually, as these motor neurons are destroyed, those affected are no longer able to walk, talk, eat, or drink. The disease ultimately becomes fatal when the motor neurons controlling the lungs fail.

In some places, patients with ALS can apply through a medical marijuana program to receive oils, tinctures, concentrates, or raw cannabis buds that contain high levels of both CBD and THC. The current research to date suggests this is the best option for ALS sufferers.

By the Editors of Reader’s Digest & Project CBD : Everything You Need to Know About What It Helps, Where to Buy It, and How to Take It.

Sign up today and get timely updates from Project CBD in your inbox!

These links are from third-party sites and are provided as a courtesy to the reader.

Top conditions

© 2021 Project CBD. All rights reserved. If you wish to reproduce any of the content on this site, please contact us for reprint permission.

THC:CBD is increasingly recognised as a valuable option in the management of spasticity in ALS. The analysis of real world data, derived from a platform-based patient registry, demonstrated a wide range in the dose of THC:CBD for the treatment of ALS-related spasticity. Obviously, THC:CBD was used on the basis of individual patients’ needs and preferences. Furthermore, severe spasticity was associated with an increased number of daily THC:CBD actuations and a stronger recommendation rate on the NPS score as compared to patients with mild spasticity. Overall, patients reported outcomes as assessed by TSQM-9 revealed a high treatment satisfaction with THC:CBD. The results of our study suggest that THC:CBD may serve as an important addition to the spectrum of treatment options of spasticity in ALS. However, an important selection bias, and by that means limitation of the study, has to be considered as a 40% of patients (n = 16) discontinued THC:CBD treatment during the observation period. Further studies are warranted to confirm our results and to address the many still open issues in the therapeutic potential of THC:CBD in this disorder.

2 Ambulanzpartner Soziotechnologie APST GmbH, Westhafenstr. 1, 13353 Berlin, Germany

Total score for effectiveness: ([sum (response score for question 1 plus question 2 plus question 3) minus 3] divided by 18) multiplied by 100.

Conclusion

Data were collected among ALS patients who were treated in a tertiary ALS centre in Berlin (Germany). The investigation was confined to patients treated with THC:CBD between May 2016 and September 2017. ALS trained neurologists confirmed the diagnosis of ALS according to the El Escorial criteria and made the indication for the treatment with THC:CBD. The anatomic region and severity of spasticity were classified by the neurologist (observer reported outcome). The physician’s classification of spasticity was assessed by the same investigator. The patient’s perception of spasticity (patient reported outcome) was obtained during the course of treatment. Before the patient’s assessment an instruction to the method of numeric rating scale (NRS) was performed by the investigator. Medication data on THC:CBD and other antispasmodic drugs were recorded on the basis of prescription data tracked on the APST platform. Data entry of prescription data was performed by data managers trained in the digital capture of medication data. THC:CBD was delivered via a highly standardised pump action oromucosal spray. Each 100 μL actuation contained 2.7 mg THC and 2.5 mg CBD in a 50:50 solution of ethanol and propylene glycol.

The patients’ treatment satisfaction with THC:CBD, as assessed by TSQM-9, is shown in Fig.  6 . The score was evaluated separately in the nine addressed questions, which are as follows.

TSQM-9, Question 9 (global satisfaction) – overall satisfaction THC:CBD: 91% of patients (n = 29) were, taking all things into account, reasonably satisfied to very satisfied with the medication of THC:CBD.

Mild: 1 to 3 points.